The antibody response and delayed type hypersensitivity reaction to commercially available trivalent influenza vaccine in 159 patients with diabetes mellitus was compared with response and reaction in 28 healthy volunteers. A correction for prevaccination titres was made. No differences were found between diabetic patients and control subjects with respect to antibody response to the three vaccine strains as measured by the difference between geometric mean titres of post-and prevaccination sera. In Type 1 (insulin-dependent) diabetic patients the incidence of non-responders to two vaccine components was significantly increased (p< 0.05). The delayed type hypersensitivity reaction to influenza antigen was significantly decreased in patients with high concentrations of glycosylated haemoglobin (p<0.01). These findings suggest a role for impaired immune response in the increased influenza morbidity and mortality in patients with diabetes mellitus. Implications for therapy and vaccination strategy are discussed.
Infections with influenza carry a high morbidity and mortality rate in patients with diabetes mellitus [1] [2] [3] . The increased risk of complications in these patients is generally ascribed to the occurrence of diabetic ketoacidosis [4] and secondary bacterial infection, mainly by Staphylococcus aureus [5] . Patients with diabetes mellitus are often carriers of Staphylococcus aureus, and they have been shown to have an impaired immune response to this micro-organism [6, 7] .
In order to prevent these complications, annual vaccination of diabetic patients is recommended. To accomplish protection against influenza, vaccination should induce high antibody titres against the viral haemagglutinin [8] . Simultaneously stimulated cellular immunity, though not protective, might contribute to the recovery from infections with influenza viruses [9] .
Poor antibody response to influenza vaccination has been demonstrated in various risk groups, such as renal transplant patients [10] , patients with malignant diseases [11, 12] and in the aged [13] .
In order to evaluate the immune response to influenza antigen in both Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients, we studied the antibody production and delayed type hypersensitivity reaction after vaccination with a trivalent influenza vaccine.
Subjects and methods

Subjects
Patients studied were attending the outpatient clinic of the Department of Internal Medicine of the Diakonessen Hospital, Utrecht, The Netherlands. Patients were considered to be Type I if there had been documented ketoacidosis and/or abrupt onset of symptoms requiting insulin therapy at age < 40 years and Type 2 if there had been protracted treatment with diet or oral therapy at age > 40 years. The study population consisted of 27 patients with Type 1 diabetes mellitus, 18 men and 9 women (mean age 39.3 + 13.6 years, mean duration of disease 16.5 _+ 14.0 years) and 120 patients with Type 2 diabetes mellitus, 51 men and 69 women (mean age 65.3 _+ 10.0 years, mean duration of disease 10.3 +7.1 years). Among 12 patients, 5 men and 7 women (mean age 61.9_+7.4 years), the type of' diabetes was unknown. In Type 1 diabetic patients, 5 had known cardiovascular complications, 3 were treated for retinopathy and 1 had marked neuropathy. Among Type 2 patients 37% were more than 10% overweight and 25% had major cardiovascular complications. Retinopathy was diagnosed in 16 and neuropathy in 13% of Type 2 diabetic patients. Control subjects were 28 healthy volunteers, 13 men and 15 women (mean age 50.8 _+ 17.0 years). Participants were excluded if they were allergic to egg protein or when febrile on the day of vaccination. Written consent was obtained from all participants and approval for the study was obtained from the Ethical Committee of the University Hospital Dijkzigt.
Vaccine: dosage and administration
Trivalent purified whole virus influenza vaccine (Duphar-Nederland, Amsterdam, The Netherlands) containing 10 Ixg haemagglutinin (HA) A/Philippines/2/82 (H3N2), 10 ~g HA A/Chile/I/83 (HiNt) and 15 gg HA B/USSR/100/83 was administered in 0.5 ml doses intramuscularly in the upper arm. To induce a delayed type hypersensitivity reaction, an 0.t ml dose of the same vaccine (diluted 1 : 1 with phosphate buffered saline) was inoculated into the skin of the volar aspect of the forearm.
Laboratory investigations and calculations
Blood samples were obtained prior to administration of vaccine and again 14 days later. Sera were separated immediately after blood collection and clotting and stored at -20 ~ until titration.
Influenza strains were propagated in embryonated hen's eggs. Because of the low avidity of the influenza B virus, infectious egg fluids of this strain were treated with aether according to Berlin et al. [14] and the watery phase was used in the serologic tests.
Serum haemagglutination inhibition (HI) titres were determined twice by standard methods [15] simultaneously in pre-and post-vaccination sera. Titres were expressed as reciprocals of the dilution showing 50% haemagglutination inhibition with 3 haemagglutination units of the antigen. From the results of the two determinations per serum and per antigen, the geometric means were used for further calculations. Negative titres (< 9) were arbitrarily regarded as 5.
With the method used, protection against influenza is thought to be associated with an HI titre of 100 for influenza A [8] . No protection threshold is known for aether-treated influenza B strains. For this study an HI titre of 100 was assumed to be protective.
Among diabetic patients and control subjects, those with prevaccination titres above 100 were excluded separately for each antigen. The serologic response upon vaccination was expressed using the following criteria: the response rate (i. e. the proportion of subjects with a 4-fold or greater titre increase after vaccination); the protection rate (i. e. the proportion of subjects exceeding the threshold titre of 100 after vaccination); the mean-fold increase (i. e. the difference between the logarithmated geometric mean titres of post-and prevaccination sera). peutic regimen. Results are presented for the three vaccine strains separately in Tables 1-3 . Although patients with Type 1 diabetes and those with Type 2 diabetes treated with a diet only tended to have lower antibody responses after vaccination as compared to control subjects, differences in mean-fold increase were not statistically significant. The established protection rate was high for the H3N2 strain (Table 1) , reaching 90% in control subjects and 85% in diabetic patients. Protection rates for the other two vaccine components, however, were considerably lower: 66 and 64% for H1Na and 50 and 57% for the influenza B strain (control subjects and patients, respectively). Differences were not statistically significant.
In comparison with control subjects, the incidence of patients showing a 4-fold or greater titre rise was substantially lower in Type 1 diabetes for the H3N2 and influenza B vaccine components (100 vs 78% and 80 vs 44%, respectively, p< 0.05). A significantly lower incidence of patients with a 4-fold or greater titre increase to the influenza B strain was also shown for patients treated with insulin, a major part of whom had Type I diabetes (46 vs 80% in control subjects, p< 0.01).
For patients treated with diet only, the incidence of patients with a 4-fold or greater titre increase was significantly lower for the H3N2 component (78 vs 100% in control subjects, p<0.05). There was no correlation between antibody production or response rate and the concentration of HbAtc.
Glycosylated haemoglobin
The percentage of glycosylated haemoglobin (HbAac) on the day of vaccination was determined by a commercially available column test (Bio Rad Laboratories, Richmond, Calif, USA). In short, a small quantity of whole blood is mixed with a haemolysis reagent. An aliquot of the haemolysate is then applied to a weakly acidic cation exchange resin in a disposable column. The HbAla and HbAlb fractions are first eluted by adding a buffer. The HbAlc fraction is then eluted separately by adding a second dilution/developing reagent. The relative % concentration of HbAlc is determined spectrophotometrically.
Delayed type hypersensitivity reaction (D THR)
DTHR was read after 24 h. Quantification of the test was achieved by calculating the area of induration as the product of two diameters at right angles. Diameters were measured as described previously by Sokal [17] .
Statistical analysis
Data are presented as mean+ SD. Differences in qualitative measures were tested for significance by the chi-square test, and in quantitative measures by the Wilcoxon rank test.
Results
Seroresponse
The outcome of the serologic determinations was calculated for type of diabetes mellitus and for the thera-
Delayed type hypersensitivity reaction (D THR)
In order to establish a correlation between the DTHR and the metabolic state, all 159 patients were divided into two groups according to the concentration of glycosylated haemoglobin: HbAtc 4-6.5% (within normal limits), and > 6.5%.
The largest induration was demonstrated in control subjects: 360 mm 2 (_+ 246). In patients with HbAt values within normal limits (HbAI<6.5%), the DTHR was similar to that in control subjects. In comparison with control subjects, the DTHR in patients with an HbAao>6.5% was significantly decreased (p<0.01). Results are shown in Figure 1 .
Discussion
From a previous study it was concluded that patients with well controlled diabetes mellitus respond normally to influenza immunisation. The population studied, however, was small and prevaccination titres were considerably higher in control subjects, for which no correction was made [18] . In the present study a correction was included for prevaccination titres. It is shown that, at least in patients with Type i diabetes, there is an increased incidence of non-responders to two of the three vaccine components. Humoral immune response Table 2 . Serologic response to the H1N1 vaccine component in control subjects and in patients with diabetes mellitus
Control
Diabetic patients subjects to influenza vaccination has been shown to be impaired in the elderly [13] ; however, as control subjects (mean age 50.8_+ 17.0 years) were older than Type 1 diabetic patients (mean age 34.4_+ 13.6 years), age cannot be held responsible for the increased incidence of non-responders among Type 1 patients. Antibody formation against the influenza antigen is a T-cell dependent phenomenon. In experimental animals the humoral immune response is impaired if the helper effect of T cells is lacking [19] . In patients with Type I diabetes, T-cell depletion has recently been demonstrated [20] . This may explain the increased incidence of non-responders to influenza antigen, while antibody response to pneumococcal polysaccharide, which may proceed independently of T-cell help, is not decreased [21] .
The number of patients unable to acquire a protective antibody level against the influenza B and H1N1 vaccine components is substantial. This is an important outcome, considering the high incidence of other risk factors such as cardiovascular diseases, especially in elderly diabetic patients. Barker and Mullooly [1] showed that influenza mortality is highest in patients who have cardiovascular disease in combination with either diabetes or chronic pulmonary disease. Therefore, a booster immunisation after at least 4 weeks seems to be advisable in patients with diabetes mellitus. However, results of booster vaccination in other risk groups are disappointing [10, 22] .
Decreased DTHR to candida in diabetic patients has been previously demonstrated [23] . In the same study no decreased DTHR was found for a viral antigen (mumps). Mahmoud et al. [24] showed that decreased cellular hypersensitivity in diabetic mice could be restored with insulin treatment. Our findings of a decreased DTHR in patients with high HbAlo values and not in patients with HbAtcvalues within normal limits suggest that optimal regulation might restore the DTHR in humans.
The function of T cells which mediate the DTHR in influenza infections is not clear. In mice these cells were found in the lungs after infection with an influenza A virus, the concentration of cells being correlated with the amount of virus administered [25] . For recovery from the infection, however, the cytotoxic T cell and natural killer cell are probably more important [9] .
Until now it was assumed that the main risks of influenza infection in patients with diabetes mellitus lie in the occurrence of ketoacidosis [4] and secondary bacterial infection [5] . From this study it can be concluded that impaired immune response to the influenza virus itself may contribute to increased morbidity and mortality.
